← Leaderboards
Stylianos Bournazos
Rockefeller University
$8,462,360
Attributed
$8,462,360
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,462,360 · 3
By mechanism
R01$7,123,533 · 2
U19$1,338,827 · 1
Top collaborators
No co-investigators on record.
Most similar at Rockefeller University
Same institution · by research overlap
- Jeffrey Victor Ravetch$66,226,718
- Josefina Inãs Del Marmol$884,949
- Jack Goldstein$0
- John W. Schoggins$10,987,205
- Matthew J Evans$6,693,610
Others in their field
Other Emerging Leaders on “Fc Domain”
- Taia Wang · Stanford University$7,681,882
- Erika Smith · Renetx Bio, Inc.$3,091,078
- Bradley David Gelfand · University Of Virginia$3,077,170
- Lenette Lu · Massachusetts General Hospital$3,046,549
- Andres Finzi · Univ Of Massachusetts Med Sch Worcester$2,721,696
- Guohua Yi · University Of Texas Hlth Ctr At Tyler$2,065,311
Research focus
Fc DomainAntibodiesImmunoglobulin GExhibitsPathway InteractionsMouse StrainsLeukocytesBiologicalIn VivoReceptorEngineeringCellsMonoclonal AntibodiesBiological ModelsHumanized MouseGenetically Engineered MouseIn VitroDengueAffinityAntibody-Dependent EnhancementMediatingInfectionPredispositionSeverity Of Illness
Grant awards (20)
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$459,711
R01 · FY2025 · AI · contact PI
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics$585,459
R01 · FY2024 · CA · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$459,711
R01 · FY2024 · AI · contact PI
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics$603,948
R01 · FY2023 · CA · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$477,086
R01 · FY2023 · AI · contact PI
Transgenic mouse core$231,032
U19 · FY2023 · AI · contact PI
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics$603,948
R01 · FY2022 · CA · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2022 · AI · contact PI
Transgenic mouse core$417,500
U19 · FY2022 · AI · contact PI
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics$616,273
R01 · FY2021 · CA · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2021 · AI · contact PI
Transgenic mouse core$235,347
U19 · FY2021 · AI · contact PI
Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics$633,648
R01 · FY2020 · CA · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2020 · AI · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2020 · AI · contact PI
Transgenic mouse core$235,349
U19 · FY2020 · AI · contact PI
Mechanisms of antibody-dependent enhancement of SARS-CoV-2 infection$141,249
R01 · FY2020 · AI · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2019 · AI · contact PI
Transgenic mouse core$219,599
U19 · FY2019 · AI · contact PI
Mechanisms of Antibody-Dependent Enhancement of Dengue Disease$423,750
R01 · FY2018 · AI · contact PI